Robert H. Vonderheide

TL;DR: By parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient’s tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.

TL;DR: It is reported that mouse and human PMN-MDSCs exclusively upregulate fatty acid transport protein 2 (FATP2), and FATP2 mediates the acquisition of immunosuppressive activity by PMn-M DSCs and represents a target to inhibit the functions of PMN, MDSCs selectively and to improve the efficiency of cancer therapy.

TL;DR: In this article, the authors proposed a novel artificial antigen presenting cells (aAPC) that can be used as an off-the-shelf APC to expand a T cell of interest.

TL;DR: It is reported that CD40 activation can provide an immunological “missing link” by priming T cells and synergizing with immune checkpoint blockade in a highly refractory pancreas cancer genetic mouse model, enabling T cell priming that is otherwise unachievable in pancreatic cancer.

TL;DR: These precursors are barely detectable in steady state conditions and are not consequential for differentiation of granulocytes, but they accumulate in cancer and substantially contribute to PMN-MDSC expansion.